The in vitro interactions between bismuth subcitrate and a variety of antimicrobial agents against 12 Campylobacter pyloridis (C. pylorn) isolates were studied by the agar dilution checkerboard technique. The combination of bismuth subcitrate with the older quinolone, oxolinic acid, produced synergistic activity against all strains. This observation, however, could not be extended to the (aryl) fluoroquinolones, norfloxacin, ofloxacin, and difloxacin, since synergy was rare or absent when bismuth subcitrate was combined with these antibiotics. Among the other antimicrobial agents tested, rifampin and the beta-lactams frequently showed synergistic interactions with bismuth subcitrate. Nifuroxazide, a nitrofuran which is not significantly absorbed, showed MICs for C. pyloridis similar to those of bismuth subcitrate.
Antimicrobial chemotherapy is helping to clarify the role of Campylobacter pyloridis (C. pylori) in the pathogenesis of gastritis. Histological studies have demonstrated that gastritis is cured after the organism is eradicated from the gastric mucosa (6, 9) .
A variety of antimicrobial agents display good activity against C. pyloridis in vitro (1, 5, 8 ). Yet when tested as single agents in clinical studies, they do not succeed in eradicating the organism. Failure of therapy and relapse are very common (10) . The reason for this discrepancy between in vitro and clinical results has not been established. Possible explanations are poor penetration of the compounds in gastric mucus, destruction at acid pH, or both. The best results so far have been achieved with the combination of a nonabsorbed agent with topical activity, colloidal bismuth subcitrate, and a well-absorbed agent with systemic activity, amoxycillin (10) . But clearly, therapy for C. pyloridisassociated infections still is suboptimal.
The purpose of this study was to select, on the basis of synergistic activity in vitro, advantageous partner compounds for bismuth salts for combination therapy against C. pyloridis.
The antibiotics (ampicillin, cefaclor, difloxacin, erythromycin, metronidazole, minocycline, nifuroxazide, nitrofurantoin, norfloxacin, ofloxacin, oxolinic acid, polymyxin B, rifampin, and tobramycin) were provided by the manufacturers. Bismuth subcitrate was obtained from Gist-Brocades nv, Delft, The Netherlands.
The organisms which were tested were 12 recent C. pyloridis isolates obtained from antrum biopsies from patients at the University Hospital, Antwerp, Belgium. One isolate from each patient was tested. The identification of isolates was based on standard biochemical tests (7) .
Antibiotic solutions were prepared in appropriate buffer solutions, distilled water, or both. Bismuth subcitrate powder was brought into colloidal suspension in 1 N NaOH and further diluted in distilled water.
Antibacterial activity was determined by the agar dilution technique, with Mueller-Hinton agar (GIBCO Diagnostics, Madison, Wis.) supplemented with 10% sterile defibrinated * Corresponding author.
horse blood to support growth of the organism. The inoculum, a 1-,ul suspension of 104 viable cells, was obtained by diluting a suspension (0.5 McFarland standard) containing approximately 108 CFU/ml in brain heart infusion broth (GIBCO Diagnostics). The inoculum was applied with a multipoint inoculator.
The MIC was the lowest concentration that inhibited visible growth of organisms on agar after 72 h of microaerobic incubation at 37°C (5% 02 and 10% CO2 in N2 at 98% humidity). The MIC50 and MIC90 were the lowest concentrations that inhibited 50 and 90% of the isolates, respectively.
Synergism between bismuth subcitrate and the test antibiotics was quantitated by the simplified agar dilution checkerboard technique, as described by Krogstad and Moellering (4). Equal and successively lower concentrations of both compounds, starting with 8x MIC50 of bismuth subcitrate and 8 x MIC5o of the test antibiotic, were examined. This arrangement considerably reduced the number of agar plates needed while retaining sufficient discrimination at the midpoint to determine the presence of synergistic inhibition or growth. Agar dilution was preferred to broth dilution because of the difficulty of interpreting growth inhibition in broth in the presence of colloidal bismuth subcitrate.
For quantitation of synergism, fractional inhibitory concentration (FIC) indices were calculated with the following In an additional experiment, the influence of pH on the activity of the arylfluoroquinolone, difloxacin, and the fluoroquinolone, ofloxacin, against C. pyloridis was evaluated by a microdilution broth procedure. Brain heart infusion broth supplemented with 0.25% yeast extract and 10% horse serum was prepared at pH 7.3, 6.3, or 4.9 with appropriate buffer solutions. Suspensions of three C. pyloridis strains and solutions of the antibiotics were then prepared in the broth. For the preparation and inoculation of microdilution trays, standard techniques were used (3).
ANTIMICROB. AGENTS CHEMOTHER. The activities of the 15 antimicrobial agents against the 12 C. pyloridis strains are shown in Table 1 . Ampicillin and minocycline were the most potent compounds (MIC90, 0.125 p.g/ml). Nifuroxazide (MIC90, 4 jig/ml), a compound with poor gastrointestinal absorption, was as effective or more effective than bismuth subcitrate (MIC90, 8 ,ug/ml), which also is not absorbed.
The results of synergy testing are shown in Table 2 . Synergistic activity was observed against all isolates when oxolinic acid was combined with bismuth subcitrate, but such activity was absent when the latter was combined with difloxacin, nitrofurantoin, ofloxacin, or tobramycin. The activities with the other combinations fell between these two extremes. No antagonism was observed.
No growth of C. pyloridis was observed at pH 4.9. At pH 6.3, MICs of difloxacin and ofloxacin for the three C. pyloridis strains were one dilution lower than those at pH 7.3. The most effective activity was thus obtained at neutral pH.
There is a growing awareness of the differences between the mechanisms of action of older (oxolinic acid) and newer (difloxacin, norfloxacin, and ofloxacin) quinolone antibiotics (11) . The striking difference between the synergistic activity against C. pyloridis when bismuth subcitrate is combined with oxolinic acid and when it is combined with difloxacin, norfloxacin, or ofloxacin supports this idea.
The more effective synergistic results observed with oxolinic acid in this study do not guarantee any therapeutic results in vivo. However, they confer some priority to in vivo studies assessing the therapeutic efficacy of bismuth salts plus oxolinic acid in C. pyloridis-associated gastritis.
Activity at low pH should not be a major consideration when an appropriate antibiotic against C. pyloridis is chosen. The organism does not survive at pH 4.9. Indeed, C. pyloridis does not live in the gastric lumen but rather under the gastric mucus, where it is protected from acid pHs (7) .
Another interesting feature is the effective activity of nifuroxazide against C. pyloridis. Nitrofurans are bactericidal agents, and nifuroxazide is not absorbed significantly 
